Qingdao Haier Biomedical Co., Ltd. announced that the company and Shanghai RAAS Blood Products are planning to use Qingdao Haier Biomedical Co., Ltd. to issue A-shares to all shareholders of Shanghai RAAS Blood Products as a way to carry out a share exchange and merge with Shanghai RAAS Blood Products, as well as raise supporting funds by issuing A-shares. Due to the planning of a major asset restructuring matter, the company's securities will be suspended from trading starting December 23, 2024, for a period not exceeding 10 trading days. As of the date of this announcement, the company and relevant parties are actively promoting the relevant work for this transaction.